Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Clinical Pharmacology and Therapeutics
|
November 17, 2017
Industry Perspective on Biomarker Development and Qualification
Cory V Gerlach, Mazin Derzi, Shashi K Ramaiah, et al.
Regulatory Toxicology and Pharmacology : RTP
|
June 12, 2012
Evaluation of sitaxentan (Thelin®) toxicity in juvenile rats and regulatory interactions during the development of a European Medicines Agency pediatric investigation plan
David M Cross, Mazin Derzi, Elizabeth Horsley, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology
|
August 15, 2012
An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats
David M Cross, Elizabeth Horsley, Mazin Derzi, et al.
Regulatory Toxicology and Pharmacology : RTP
|
June 12, 2012
An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension
Keith Owen, David M Cross, Mazin Derzi, et al.
Clinical Pharmacology and Therapeutics
|
October 15, 2019
Evaluation of Therapeutics for Severely Debilitating or Life-Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development
Maggie Liu, F Owen Fields, Judith S Prescott, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 10, 2017
Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective
Lynne D Butler, Peggy Guzzie-Peck, James Hartke, et al.
Regulatory Toxicology and Pharmacology : RTP
|
February 2, 2020
Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab
Mazin Derzi, Ahmed M Shoieb, Sharon L Ripp, et al.
Clinical Pharmacology and Therapeutics
|
December 30, 2017
An Industry Perspective on the 2017 EMA Guideline on First-in-Human and Early Clinical Trials
Joseph DeGeorge, Sarah Robertson, Lynne Butler, et al.
Advances in Therapy
|
September 3, 2016
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade<sup>®</sup> (Infliximab)
Mazin Derzi, Theodore R Johnson, Ahmed M Shoieb, et al.
The Journal of Toxicological Sciences
|
March 1, 2021
Microphysiological systems in early stage drug development: Perspectives on current applications and future impact
Anna K Kopec, Ryuji Yokokawa, Nasir Khan, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Clinical Pharmacology and Therapeutics
|
November 17, 2017
Industry Perspective on Biomarker Development and Qualification
Cory V Gerlach, Mazin Derzi, Shashi K Ramaiah, et al.
Regulatory Toxicology and Pharmacology : RTP
|
June 12, 2012
Evaluation of sitaxentan (Thelin®) toxicity in juvenile rats and regulatory interactions during the development of a European Medicines Agency pediatric investigation plan
David M Cross, Mazin Derzi, Elizabeth Horsley, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology
|
August 15, 2012
An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats
David M Cross, Elizabeth Horsley, Mazin Derzi, et al.
Regulatory Toxicology and Pharmacology : RTP
|
June 12, 2012
An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension
Keith Owen, David M Cross, Mazin Derzi, et al.
Clinical Pharmacology and Therapeutics
|
October 15, 2019
Evaluation of Therapeutics for Severely Debilitating or Life-Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development
Maggie Liu, F Owen Fields, Judith S Prescott, et al.
Regulatory Toxicology and Pharmacology : RTP
|
May 10, 2017
Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective
Lynne D Butler, Peggy Guzzie-Peck, James Hartke, et al.
Regulatory Toxicology and Pharmacology : RTP
|
February 2, 2020
Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab
Mazin Derzi, Ahmed M Shoieb, Sharon L Ripp, et al.
Clinical Pharmacology and Therapeutics
|
December 30, 2017
An Industry Perspective on the 2017 EMA Guideline on First-in-Human and Early Clinical Trials
Joseph DeGeorge, Sarah Robertson, Lynne Butler, et al.
Advances in Therapy
|
September 3, 2016
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade<sup>®</sup> (Infliximab)
Mazin Derzi, Theodore R Johnson, Ahmed M Shoieb, et al.
The Journal of Toxicological Sciences
|
March 1, 2021
Microphysiological systems in early stage drug development: Perspectives on current applications and future impact
Anna K Kopec, Ryuji Yokokawa, Nasir Khan, et al.
Page
of 1